These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32304215)

  • 21. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
    Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
    J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
    Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
    Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Hemagglutinin Stem Vaccine Designed Rationally by AlphaFold2 Confers Broad Protection against Influenza B Infection.
    Zeng D; Xin J; Yang K; Guo S; Wang Q; Gao Y; Chen H; Ge J; Lu Z; Zhang L; Chen J; Chen Y; Xia N
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals.
    Henry C; Zheng NY; Huang M; Cabanov A; Rojas KT; Kaur K; Andrews SF; Palm AE; Chen YQ; Li Y; Hoskova K; Utset HA; Vieira MC; Wrammert J; Ahmed R; Holden-Wiltse J; Topham DJ; Treanor JJ; Ertl HC; Schmader KE; Cobey S; Krammer F; Hensley SE; Greenberg H; He XS; Wilson PC
    Cell Host Microbe; 2019 Mar; 25(3):357-366.e6. PubMed ID: 30795982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
    Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and genetic basis for development of broadly neutralizing influenza antibodies.
    Lingwood D; McTamney PM; Yassine HM; Whittle JR; Guo X; Boyington JC; Wei CJ; Nabel GJ
    Nature; 2012 Sep; 489(7417):566-70. PubMed ID: 22932267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.
    Lee J; Boutz DR; Chromikova V; Joyce MG; Vollmers C; Leung K; Horton AP; DeKosky BJ; Lee CH; Lavinder JJ; Murrin EM; Chrysostomou C; Hoi KH; Tsybovsky Y; Thomas PV; Druz A; Zhang B; Zhang Y; Wang L; Kong WP; Park D; Popova LI; Dekker CL; Davis MM; Carter CE; Ross TM; Ellington AD; Wilson PC; Marcotte EM; Mascola JR; Ippolito GC; Krammer F; Quake SR; Kwong PD; Georgiou G
    Nat Med; 2016 Dec; 22(12):1456-1464. PubMed ID: 27820605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza virus antibodies inhibit antigen-specific
    Goodwin E; Gibbs JS; Yewdell JW; Eisenlohr LC; Hensley SE
    J Virol; 2024 Sep; 98(9):e0076624. PubMed ID: 39194245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
    Zost SJ; Wu NC; Hensley SE; Wilson IA
    J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outflanking immunodominance to target subdominant broadly neutralizing epitopes.
    Angeletti D; Kosik I; Santos JJS; Yewdell WT; Boudreau CM; Mallajosyula VVA; Mankowski MC; Chambers M; Prabhakaran M; Hickman HD; McDermott AB; Alter G; Chaudhuri J; Yewdell JW
    Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13474-13479. PubMed ID: 31213541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine approaches conferring cross-protection against influenza viruses.
    Vemula SV; Sayedahmed EE; Sambhara S; Mittal SK
    Expert Rev Vaccines; 2017 Nov; 16(11):1141-1154. PubMed ID: 28925296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza vaccination strategies targeting the hemagglutinin stem region.
    Fukuyama H; Shinnakasu R; Kurosaki T
    Immunol Rev; 2020 Jul; 296(1):132-141. PubMed ID: 32542739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses.
    Guthmiller JJ; Lan LY; Fernández-Quintero ML; Han J; Utset HA; Bitar DJ; Hamel NJ; Stovicek O; Li L; Tepora M; Henry C; Neu KE; Dugan HL; Borowska MT; Chen YQ; Liu STH; Stamper CT; Zheng NY; Huang M; Palm AE; García-Sastre A; Nachbagauer R; Palese P; Coughlan L; Krammer F; Ward AB; Liedl KR; Wilson PC
    Immunity; 2020 Dec; 53(6):1230-1244.e5. PubMed ID: 33096040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.